Please provide a comprehensive summary of NCCN guidelines for my Stage IV Lung. What are the standard treatment...

According to the NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC), the first step is to conduct biomarker testing to determine the most appropriate treatment approach. Here are the key treatment pathways:

1. Biomarker-Driven Treatment: According to NCCN Guidelines, testing should include:

• EGFR mutations
• ALK rearrangements
• ROS1 rearrangements
• BRAF mutations
• PD-L1 expression
• NTRK fusions

1. First-line Treatment Options: The American Society of Clinical Oncology (ASCO) and NCCN recommend:

If biomarker positive:

• EGFR mutations: Targeted therapies like osimertinib
• ALK positive: ALK inhibitors like alectinib or brigatinib
• ROS1 positive: Entrectinib or crizotinib

If no actionable mutations but PD-L1 ≥50%:

• Pembrolizumab monotherapy
• Or combination chemotherapy plus immunotherapy

For PD-L1 <50%:

• Combination chemotherapy plus immunotherapy

1. The National Cancer Institute (NCI) emphasizes that treatment goals for Stage IV focus on:

• Prolonging survival
• Managing symptoms
• Improving quality of life
• Controlling disease progression

Important considerations:

• Treatment choices should be individualized based on your specific biomarker results
• Performance status and overall health affect treatment options
• Clinical trials may be available and should be considered at any point

Please note: This is a general overview, and your specific treatment plan should be determined by your oncology team based on your individual case. Would you like me to elaborate on any particular aspect of these guidelines?